Journal of Blood & Lymph

Katrin Herzog-Tzarfati

Publications

• Research Article
  Atypical Infections in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Patients Treated with Ibrutinib
  Author(s): Filipovich Rimon, Miriam Wienberger, Katrin Herzog-Tzarfati, Naomi Rahimi-Levene, Marina Izak, Odit Gutwein, Talia and Maya Koren-MichowitzFilipovich Rimon, Miriam Wienberger, Katrin Herzog-Tzarfati, Naomi Rahimi-Levene, Marina Izak, Odit Gutwein, Talia and Maya Koren-Michowitz
  
  Ibrutinib is an oral Bruton’s tyrosine kinase inhibitor with clinical efficacy in several B cell malignancies. In a pooled analysis of clinical trials evaluating ibrutinib, grade 3-4 infections were reported in 14% of patients. We screened consecutive patients on ibrutinib therapy for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) for infectious complications. Patients were hospitalized with documented infections uncommon to this patient population including Legionella pneumonia, Campylobacter bacteremia and fatal progressive multifocal leukoencephalopathy (PML). All patients received prior therapies for CLL/MCL. Immunological evaluation of these patients demonstrated immunoglobulin depression and profound lymphopenia with severe depletion in both B and CD4 T cell counts, suggesting defects in both humoral and T cell mediated immunity. This data support a broad.. Read More»
  DOI: 10.4172/2165-7831.1000174

  Abstract PDF